John Fletcher, MBA | Board Chair
Mr. Fletcher is managing partner of Fletcher Spaght Ventures, a venture capital fund. He is also the founder and CEO of Fletcher Spaght, Inc., a consulting firm that provides growth-focused strategy assistance to client companies. He has more than 30 years’ experience providing strategy and financing assistance to companies seeking to maximize the value of their innovation. Before launching FSI in 1983, Mr. Fletcher was a senior manager at The Boston Consulting Group. Previously, he was a Ph.D. candidate and instructor in international business at The Wharton School, University of Pennsylvania. Prior to Wharton, he was a Captain and jet pilot in the US Air Force.

Mr. Fletcher is a current or past board member for many companies, including Spectranetics, Axcelis, AutoImmune, GlycoFi, NMT Medical, Quick Study Radiology, Alimed, Fischer Imaging and Panacos Pharmaceuticals. He also is or has been, a board member of many non-profit organizations including Board of Overseers of Beth Israel Deaconess Hospital, The Cardiology Council, Board of Overseers of Children's Hospital of Boston and the Board of Advisors of the Boston University Photonics Center. His current and past board memberships also include various academic institutions – the Whitehead Institute at MIT, the Masters in Engineering Management program at Thayer School of Engineering and the Tuck School of Business at Dartmouth College, and the School of Government and Business at George Washington University. He holds an MBA from Southern Illinois University and a Bachelor of Business Administration from George Washington University.

John Ryals, PhD | Chair Emeritus
Dr. Ryals served as president and CEO at Metabolon from 2002 until 2018. Before founding Metabolon, he was CEO, president and founder of Paradigm Genetics, Inc., a publicly traded agriculture biotechnology company focused on industrializing the process of gene function discovery. Dr. Ryals has 30 years of experience in the biotechnology industry, including senior research positions at Novartis and Ciba-Geigy. He currently serves on the Board of Directors of AgBiome, a provider of early-stage R&D for agriculture, and the advisory board of the College of Agriculture and Life Sciences at North Carolina State University. He earned a Bachelor of Arts in biology and chemistry from the University of North Texas and masters and doctorate degrees from the University of Texas at Dallas.

Scott Barry, MBA
Mr. Barry has more than 20 years of experience in investment banking and the healthcare industry. He joined EW Healthcare Partners (formerly Essex Woodlands) as principal in the New York office in 2006 and was quickly promoted to partner in 2008, then to managing director in 2012. Before that, Mr. Barry served as the global head of pharmaceutical M&A and collaborations at Novartis Pharma AG and was responsible for global acquisitions, equity investments, and corporate partnerships across all therapeutic areas. He joined Novartis in 2002 and held positions in the business development and licensing and mergers and acquisitions groups. Before joining Novartis, Mr. Barry was a director for Century Capital Associates LLC, a boutique healthcare investment bank and consulting firm, focusing on mergers and acquisitions, strategic partnering and financing transactions. He also has held positions at KPMG LLP in their healthcare corporate finance and assurance services groups.

Mr. Barry previously served on the Board of Directors of Orthovita, Inc. (NASDAQ: VITA) acquired by Stryker Corporation; Victory Pharma, Inc., acquired by Shionogi, Inc., and Velcera, acquired by Perrigo Company. He is currently on the Board of Directors for Breg/United Orthopedic Group and Encore Dermatology. He holds a Bachelor of Arts from Wesleyan University and an MBA from New York University.

Jeff Clark, MBA
Mr. Clark is a managing general partner at The Aurora Funds, a venture capital firm he co-founded in 1994. Working primarily with Aurora's life sciences portfolio, he leads Aurora's healthcare team to identify new investment opportunities and support approximately 30 healthcare portfolio companies. He currently serves as a director of Cardioxyl Pharmaceuticals, Hyperbranch Medical Technology, Regado Biosciences and Neotropix, Inc. Before forming Aurora, Mr. Clark spent 13 years working in development and external affairs for Duke University (including Duke Comprehensive Cancer Center, Duke Medical Center and the School of Engineering). He serves on the Board of Overseers of the Duke Comprehensive Cancer Center and Board of Advisors of the Center for Entrepreneurship and Innovation at the Duke University Fuqua School of Business. Mr. Clark also supports the entrepreneurial efforts of the greater RTP community by having served as chairman of North Carolina's Council for Entrepreneurial Development (CED) and as a co-founder of North Carolina Initiative for Innovation and Entrepreneurship (NCIIE). He holds a Bachelor of Science in mechanical engineering and an MBA from Duke University.

Rohan F. Hastie, PhD | President & Chief Executive Officer, Metabolon
Dr. Rohan F. Hastie has served as president and CEO at Metabolon since May 2018. He leads the company’s vision to harness the power of its Precision Metabolomics™ Platform to provide biological insights of disease state and physiological reactions in the present time. As the global leader in metabolomics, Metabolon offers the world’s most extensive – and continuously growing – metabolomics knowledge base. The company’s deep metabolomic insights are addressing some of the most challenging and pressing questions in the life sciences, helping to advance success in the biopharma, consumer products, and academic research sectors.

Before joining Metabolon, he was president of Arrow Life Sciences & Healthcare, a consulting firm specializing in commercialization and operational excellence for life sciences companies. He also held various senior leadership positions in diagnostics and corporate development at Hologic, Inc., including president of Hologic Diagnostics where he grew the business into one of the world’s leading diagnostics companies with more than 1800 employees and $1.25 billion in annual revenue. Earlier in his career, Dr. Hastie worked at the strategy consulting company PA Consulting Group in their Life Sciences and Technology group, consulting for a wide range of companies in the pharmaceutical, biotechnology and diagnostics industries. He earned his doctorate in molecular genetics from Queen Elizabeth Medical School in Birmingham, England and a degree in biological sciences from the University of Birmingham.

Rudy Howard, CPA
Mr. Howard is the chief financial officer of vTv Therapeutics, a publicly held, clinical-stage pharmaceutical company. Before joining vTv, he was CFO at SciQuest, Inc., an international spend-management software company. Mr. Howard has also served as CFO for several other public and private multi-national companies in the life sciences and software industries, including MDS Pharma Services and Pharmaceutical Product Development (PPD). Mr. Howard spent the first half of his career in public accounting, where he became an assurance partner with PricewaterhouseCoopers. He served clients in the pharmaceutical, biotechnology, high technology and financial services industries. Among his areas of expertise were public company disclosure compliance, including guiding numerous clients through the IPO process, and merger and acquisition consulting. Mr. Howard is a certified public accountant and received his Bachelor of Arts in accounting from North Carolina State University.

Jan Lundberg, PhD
Dr. Lundberg has two decades of executive leadership experience in the pharmaceutical sector and held c-suite positions with leading companies, including Eli Lilly and AstraZeneca. Through his leadership, he has overseen the development of more than 200 candidate drugs, with 22 approved products across multiple therapeutic areas. Before joining AstraZeneca, Dr. Lundberg held the position of Professor of Pharmacology at the Karolinska Institute in Solna, Sweden. In addition to his significant industry experience, Dr. Lundberg is the co-founder of Aerocrine AB and currently serves on the boards of Ardelyx, Betagenon Image Analysis Group, and TB Alliance. He has also been a member of several government committees in both the European Union and the United States. Dr. Lundberg completed his undergraduate studies at the University of Gothenburg, earning a Bachelor of Science degree in medicine, and his doctorate at the Karolinska Institute.

John Oxaal, MBA
Mr. Oxaal is a general partner at Sevin Rosen Funds, where he focuses on the areas of imaging, computing, photonics, RF communications, and semiconductors. Before joining Sevin Rosen Funds in 1999, he co-founded and was CEO of Volumetrics Medical Imaging, Inc., a developer of three-dimensional ultrasound technology, and was on the founding team of the digital signal processing division of Analog Devices, Inc. Mr. Oxaal holds several patents in the field of real-time volumetric ultrasound imaging. In addition to continuing as the chairman of the Volumetrics Board, he serves on the boards of Airwavz Solutions, Inc., Ethertronics, Inc., Luxtera, Inc., and Scintera Networks, Inc. He holds a Bachelor of Science in biomedical engineering from Duke University and an MBA from the University of Chicago. Mr. Oxaal is on the Board of Visitors at the Duke University Pratt School of Engineering and the Polsky Center for Entrepreneurship at the University of Chicago.

David Pierson, MBA
Mr. Pierson is managing director for Syngenta Ventures, the corporate venture capital unit of Syngenta AG. Syngenta makes venture investments in companies with a broad range of technologies applicable to agriculture. Before joining Syngenta in 2012, he was a partner at Intersouth Partners, a life science and technology venture capital firm with $800 million in capital under management. Before that, Mr. Pierson held numerous senior management positions in marketing, sales, and new product commercialization at Johnson & Johnson, Pharmacia (now Pfizer) and NPS Pharmaceuticals. He has served as a director or observer for 16 venture-backed companies including Novamin Technologies (acquired by GSK), Athenix Biosciences (acquired by Bayer Crop Science), Proteon Therapeutics (Nasdaq PRTO), and Argos Therapeutics (Nasdaq ARGS). He holds a Bachelor of Science in engineering with a concentration in international relations from the United States Military Academy at West Point and an MBA from the Fuqua School of Business at Duke University. Following graduation from West Point, he served as an officer in the 82nd Airborne Division, Ft. Bragg, N.C., and with the 2nd Infantry Division deployed along the demilitarized zone in the Republic of Korea.

Todd Schermerhorn, MBA
Mr. Schermerhorn is the retired senior vice president and chief financial officer of C. R. Bard, Inc. He joined Bard in 1985 as a cost analyst and progressed through a series of management positions including controller, vascular division; vice president and controller, USCI division; vice president and group controller, cardiology division. He was elected vice president and treasurer of Bard in 1998 and later was appointed the senior vice president and CFO, a position held for 10 years until his retirement from the company. Mr. Schermerhorn previously served on the boards of Thoratec Corporation, which was acquired by St. Jude Medical, Inc., and The Spectranetics Corporation, which was acquired by Royal Philips. He currently serves on the board of The Travelers Companies, Inc. In addition, he has served on the board of several non-profits including Somerset Medical Center, Cornerstone Family Programs and the Sean Reilly TBI Fund. Mr. Schermerhorn holds a Bachelor of Science in accounting from the University of Massachusetts Lowell and an MBA in finance from Babson College. He is a Certified Management Accountant.